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Abstract. Ewing's sarcoma is the second most common
primary sacral tumor. Ewing's sarcomas are rare, aggressive
tumors with a tendency towards recurrence following resection
and early metastasis. Although peak incidences are between
the ages of 10 and 20 years, patients of younger or older age
account for almost 30% of the cases. We report the case of
a 52-year-old healthy female who presented with a 2-week
history of pain in her right posterior thigh that was unable to
be relieved by non‑steroidal anti-inflammatory medicine and
physical therapy. Magnetic resonance imaging demonstrated an
irregular right presacral mass and core needle biopsy revealed
a small, round blue cell neoplasm. Staging workup was normal
and an open biopsy was positive for the ES translocation
(22q12). The patient was treated with 17 cycles of vincristine,
adriamycin and cytoxan with mesna rescue, alternating with
ifosfamide and etoposide in addition to external beam radiation. Post-treatment imaging demonstrated complete resolution
of the tumor. Six weeks post‑treatment the patient presented
with a recurrent tumor. This case emphasizes the importance
of timely establishment of initial diagnosis, early metastasis
in treatment responsive patients and under-utilization of positron emission tomography-computed tomography (PET-CT)
during the treatment to detect sub-clinical metastasis.
Introduction
Ewing's sarcoma (ES) is the second most common bone
tumor after osteosarcoma in children and adolescents. ES
are aggressive tumors with a tendency towards recurrence
following resection and pronounced proclivity toward early
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hematogenous metastases to lungs and bone. No hereditary or
congenital syndromes, environmental or known risk factors
have been associated with the occurrence of ES. In 90% of
cases, Ewing's sarcoma family tumor (ESFT) cells harbor the
translocation t(11;22)(q24;q12), and in the remaining 10% the
variant translocation is t(21;12)(22;12) (1,2). Although peak
incidence occurs between the ages of 10 and 20 years, patients
of younger or older ages account for almost 30% of the
cases (3). Poor prognostic factors include tumor ≥8 cm, pelvic
primary, presence of metastases and age >15 at the time of
diagnosis (4). Older patients with sarcoma also have a higher
risk of thromboembolism (5).
Case report
A 52-year-old healthy female presented with a 2-week history
of pain in her right posterior thigh. The pain originated in the
patient's right buttock and radiated to the back of the knee
without a radicular component. Motor strength, sensory function and reflexes were normal. Musculoskeletal examination
was within normal limits without tenderness of the hips or back.
Despite the use of non-steroidal anti-inflammatory medications and physical therapy the pain persisted. On subsequent
reassessment, a radicular component was present. Magnetic
resonance imaging (MRI) demonstrated an irregular-shaped
right presacral mass with heterogeneous short T1 inversion
recovery (STIR) hyperintensity (Fig. 1A) and T1 hypointensity (Fig. 1B). Additional evaluation with computed
tomography (CT) of the pelvis revealed a complex mass with
central necrosis and a thick enhancing wall extending into the
right S2 neural foramen with lytic bone destruction (Fig. 1C)
measuring 6x6x5 cm with compression of the right piriformis
muscle posteriorly (Fig. 1D). No adenopathy or correlation to
gynecologic structures of the pelvis were found.
An initial core needle biopsy of the mass revealed a small,
round blue cell neoplasm, suggestive of a primitive neuroectodermal tumor. The tumor was markedly positive for vimentin
(Fig. 2A) and CD99 (Fig. 2B). Staging workup with a positron emission tomography-computed tomography (PET-CT)
image (Fig. 3A) demonstrated a large avid fluorodeoxyglucose
(FDG) uptake at the level of the lower sacrum measuring
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Figure 1. A lumbar spine MRI shows an irregular shaped right presacral mass (arrow) with (A) heterogeneous STIR hyperintensity and (B) T1 hypointensity.
(C) CT of the pelvis shows a complex mass (arrow) with central necrosis and a thick enhancing wall extending into the right S2 neural foramen with lytic bone
destruction. (D) Pelvic CT shows a 6x5x6 cm mass (arrow) compressing the right piriformis muscle posteriorly. CT, computed tomography.

A

B

Figure 2. Tissue biopsy revealed a small, round blue cell neoplasm. Immunohistochemistry stains were positive for (A) vimentin and (B) CD99.

approximately 5.8 cm. There was no other area of abnormally
increased uptake of FDG in the whole body PET-CT. An
open biopsy revealed a better preserved tumor with identical
histological features testing positive for the ES translocation
(22q12), and a diagnosis of ES stage III (T2bN0M0) was made.
The patient was treated with 17 cycles of vincristine
2 mg/m2, doxorubicine 75 mg/m2, cyclophosphamide
1200 mg/m2 with mesna rescue alternating with ifosfamide
1800 mg/m2 and etoposide 100 mg/m2 (IE) as described by
Grier et al (6). Re-assessment after four cycles demonstrated
a significant response. The involvement of S1 and S2 nerve
roots represented a significant surgical challenge. As a result,
the patient received external beam radiation at a dose of 56 Gy
followed by 13 additional cycles of adjuvant chemotherapy.
Post-treatment CT of the pelvis demonstrated a near complete
resolution of the mass with minimal residual infiltrative soft

tissue changes within the right presacral space. PET imaging
demonstrated normalization of FDG uptake within the pelvic
mass (Fig. 3B). Six weeks post-adjuvant chemotherapy, the
patient presented with acute shortness of breath. PET-CT
demonstrated an area of increased FDG uptake within the
bilateral pulmonary hila, representing interval development of
metastatic disease. A subsequent biopsy of the lung confirmed
the diagnosis of metastatic ES. Two weeks later the patient
succumbed to the disease after opting for comfort care.
Discussion
The mortality rate for ES is extremely high when treated
with surgery or radiation therapy alone for local control of
the disease (7). Over the past 5 decades, advances in chemotherapy, surgery and radiation therapy have improved the
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Figure 3. (A) PET-CT image at the level of the lower sacrum demonstrated a large avid fluorodeoxyglucose (FDG) uptake within the sacral mass measuring approximately 5.8 cm. (B) Post-treatment PET/CT image shows normalization of FDG uptake within the pelvic mass. PET-CT, positron emission
tomography-computed tomography.

prognosis of patients with ESFTs (8). The limited number of
patients over the age of 40 and the exclusion of these patients
from the majority of trials render these findings difficult to
generalize (9).
Tumors of the pelvis have a poorer prognosis when
compared with other sites. Whether this is related to the challenge of achieving local control or the proximity to critical
deep structures remains to be elucidated. Current treatment
recommendations are based on the available literature that is
limited by selection bias, small study size, non-standard radiation therapy technique and lack of randomized trials comparing
the two management approaches. The role of surgery in
treating ES is controversial; however, certain studies suggest
that resection with chemotherapy and irradiation positively
impacts patient survival (10). Radiotherapy is usually applied
at doses of 40-45 Gy for microscopic residues and 50‑60 Gy
for macroscopic disease (11). Treatment of adult patients
follows the same principles. However, tolerability of therapies
in adults are taken into account when transferring treatment
protocols conceived for patients under the age of 30 years (11).
Although most cases of ES present as localized
disease, overt metastases are capable of developing rapidly.
Microscopic metastatic disease has been postulated to be
present at the time of presentation. However, its spread is held
in check by as yet unidentified factors secreted by the primary
tumor. When the primary tumor is removed or irradiated,
the loss of the putative suppressive factors may permit the
metastases to grow. The use of chemotherapy in conjunction
with surgery or radiation therapy to treat presumed metastatic
disease has substantially improved survival (12).
Beyond specific clinical trials, patients with metastatic
disease receive similar therapy to that administered for
localized disease, with appropriate local treatment of metastases, usually radiotherapy. Certain studies have suggested
benefit from intensive chemotherapy followed by autologous
stem cell rescue, but randomized trials have not yet been
performed and the benefit of stem cell transplant remains
unproven. Patients with recurrent disease fare poorly, with

5-year survival rates of less than 20% (11). Current studies
show that, following achieving remission in patients with
non-metastatic ES, 30-40% of these patients are likely to
develop recurrence of local or metastatic disease (13). The
majority of these studies report a time range of 2-10 years
between commencing treatment and development of recurrence (14). Patients relapsing later than 2 years from initial
diagnosis have more favorable outcomes (11).
This case report raises the importance of early metastasis in a treatment-responsive patient. According to current
guidelines, initial work-up for staging in a non-metastatic ES
is followed by reassessment of treatment response after 3-6
treatment cycles using focal PET-CT. In treatment responsive
ES, local therapy is followed by additional chemotherapy. A
surveillance follow-up imaging every 2-3 months for the first
three years is recommended for localized, non-metastatic
ES. The current case has demonstrated complex issues with
localized pelvic ES in an older patient who initially responded
well to chemo-radiation therapy, with complete resolution
of the tumor. Despite adequate control of the local disease,
multimodal therapy did not appear to affect metastasis.
Although sarcomas are notorious for metastasis into lungs and
bone, the utility of PET-CT and MRI for detecting subclinical
recurrence or metastases has not been established during
the treatment period. Only the primary site is evaluated by
imaging for treatment response 10-12 weeks in to therapy.
In patients with lung metastases, the resection of residual
metastases after chemotherapy, and whole lung irradiation,
may grant a survival advantage (11). Most intensive therapies with additional agents have failed to markedly increase
long‑term survival in patients with metastatic disease. The
impact of chemotherapy on metastasis of ES patients over the
age of 30 remains to be elucidated. A recent intergroup study
suggested that the addition of IE to traditional regimens may
confer a local control benefit (15). Similar effects, with the
addition of IE on survival benefit, have also been reported by
another randomized trial among patients with non-metastatic
pelvic ES (6).
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At present, patients should be offered participation in a
clinical trial when available. Barring trial participation, multimodality therapy, as described above is recommended.
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